Clinical Trials
2 trialsNCT05549037 2026-06-03
LungTIME-C01
Hunan Province Tumor Hospital
Phase 3 Completed
NCT05890742 2026-05-28
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Active not recruiting